[1]Wang LM,Englander ZK,Miller ML,et al. Malignant glioma[J]. Adv Exp Med Biol,2023,1405:1-30. doi:10.1007/978-3-031-23705-8_1. [2]Gollapalli K,Ghantasala S,Atak A,et al. Tissue proteome analysis of different grades of human gliomas provides major cues for glioma pathogenesis[J]. OMICS,2017,21:275-284.doi:10.1089/omi.2017.0028. [3]Jain R,Atak A,Yeola A,et al. Proteomic level changes associated with S3I201 treated U87 glioma cells[J]. J Proteomics,2017,150:341-350. doi:10.1016/j.jprot.2016.08.011. [4]Buczak K,Ori A,Kirkpatrick JM,et al. Spatial tissue proteomics quantifies inter- and intratumor heterogeneity in hepatocellular carcinoma(HCC)[J]. Mol Cell Proteomics,2018,17:810-825. doi:10.1074/mcp.RA117.000189. [5]Yu X,Wang M,Wu J,et al. ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway[J]. J Exp Clin Cancer Res,2019,38:40. doi:10.1186/s13046-019-1031-4. [6]Liu N,Hu G,Wang H,et al. LncRNA BLACAT1 regulates VASP expression via binding to miR-605-3p and promotes giloma development[J]. J Cell Physiol,2019,234:22144-22152.doi:10.1002/jcp.28778. [7]Schiffer D,Annovazzi L,Casalone C,et al. Glioblastoma: microenvironment and niche concept[J]. Cancers(Basel),2018,11:5.doi:10.3390/cancers11010005. [8]Zhang Q,Han Z,Zhu Y,et al. Role of hypoxia inducible factor-1 in cancer stem cells(review)[J]. Mol Med Rep,2021,23:17. doi:10.3892/mmr.2020.11655. [9]Liu P,He GC,Tan YZ,et al. PTBP1 is a novel poor prognostic factor for glioma[J]. Biomed Res Int,2022,2022:7590997.doi:10.1155/2022/7590997. [10]Liu Z,Tang C,Teng X,et al. Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment[J]. J Clin Lab Anal,2023,37:e24892.doi:10.1002/jcla.24892. [11]Wang B,Wang W,Zhu Z,et al. Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma[J]. Clin Neurol Neurosurg,2017,154:28-33. doi:10.1016/j.clineuro.2017.01.005.
|